(Q44518890)

3 December 2017

title

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model (English)

1 reference

3 December 2017

0 references

1 reference

Klement P

1

1 reference

3 December 2017

Carlsson S

2

1 reference

3 December 2017

Rak J

3

1 reference

3 December 2017

Liao P

4

1 reference

3 December 2017

Vlasin M

5

1 reference

3 December 2017

Stafford A

6

1 reference

3 December 2017

Johnston M

7

1 reference

3 December 2017

Weitz JI

8

1 reference

3 December 2017

publication date

1 March 2003

1 reference

Journal of Thrombosis and Haemostasis

3 December 2017

published in

1 reference

3 December 2017

volume

1

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

587-594

1 reference

Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Recombinant hirudin in clinical practice: focus on lepirudin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Amino acids and peptides. XVIII. Synthetic peptides related to N-terminal portion of fibrin alpha-chain and their inhibitory effect on fibrinogen/thrombin clotting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Hirudin causes more bleeding than heparin in a rabbit ear bleeding model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00060.X

10.1046/J.1538-7836.2003.00060.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference